Drug Trial Radar · NCT03683719
Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema
Last checked: Nov 20, 2026Latest source record: Mar 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
258
Actual
Start
Nov 28, 2018
Primary completion
Mar 6, 2020
Study completion Apr 20, 2020
Sponsor
- Lead sponsor
- LEO PharmaIndustry
- Sponsor type
- Industry
- First posted
- Sep 25, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this research trial was to test different strengths of a new trial medication, delgocitinib cream 1, 3, 8, and 20 mg/g, and to investigate how treatment with delgocitinib cream affects chronic hand eczema. This was judged by a range of assessments that rate the severity and extent of chronic hand eczema and its symptoms, as well as general health status and quality of life.
Conditions
- Chronic Hand Eczema
Interventions
Delgocitinib creamDrug
Cream for topical application.
Delgocitinib cream vehicleDrug
The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Investigator's Global Assessment for Chronic Hand Eczema (IGA-CHE) Score of 0 (Clear) or 1 (Almost Clear) With at Least a 2-step Improvement (IGA-CHE Treatment Success) From Baseline to Week 16.Time frame: Week 0 to Week 16.
Locations
28 sites in 3 countries. Site status is shown where the registry gives one.
Leo Pharma Investigational Site
Tucson, Arizona
Leo Pharma Investigational Site
Hialeah, Florida
Leo Pharma Investigational Site
Portland, Oregon
Leo Pharma Investigational Site
Portland, Oregon
Leo Pharma Investigational Site
Aarhus, Denmark
Leo Pharma Investigational Site
Copenhagen, Denmark
Leo Pharma Investigational Site
Hellerup, Denmark
LEO Pharma Investigational Site
Herlev, Denmark
Leo Pharma Investigational Site
Berlin, Germany
Leo Pharma Investigational Site
Bochum, Germany
Leo Pharma Investigational Site
Bremerhaven, Germany
Leo Pharma Investigational Site
Dresden, Germany
Leo Pharma Investigational Site
Düsseldorf, Germany
Leo Pharma Investigational Site
Gera, Germany
Leo Pharma Investigational Site
Göttingen, Germany
Leo Pharma Investigational Site
Jena, Germany
Leo Pharma Investigational Site
Kiel, Germany
Leo Pharma Investigational Site
Kiel, Germany
Leo Pharma Investigational Site
Langenau, Germany
Leo Pharma Investigational Site
Lübeck, Germany
Leo Pharma Investigational Site
Mahlow, Germany
Leo Pharma Investigational Site
Mainz, Germany
Leo Pharma Investigational Site
Memmingen, Germany
Leo Pharma Investigational Site
München, Germany
Leo Pharma Investigational Site
Selters, Germany
Leo Pharma Investigational Site
Stuttgart, Germany
Leo Pharma Investigational Site
Stuttgart, Germany
Leo Pharma Investigational Site
Wuppertal, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.